Investigating significant health trends in growth hormone treatments registry: rationale, aims and design of a nationwide prospective registry (study protocol) [PDF]
Orphanet Journal of Rare Diseases, 2023 Background Somatropin treatment is indicated in a variety of disorders including growth hormone (GH) deficiency, Prader–Willi and Turner syndrome, chronic renal insufficiency and others. To date, almost all studies have been limited to single GH products,
Dirk Schnabel +6 more
doaj +4 more sources
Effect of TAT-signaling fusion system along with co-expression of GroEL/ES chaperones on secretory expression of somatropin [PDF]
BioTechnologia, 2020 Human growth hormone (somatropin) is one of the most widely used recombinant proteins that stimulates growth, cell reproduction, and cell regulation in humans.
Mohammad Rabbani +3 more
doaj +4 more sources
Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report [PDF]
Frontiers in SurgeryBackgroundAnterior cervical osteophytes can compress the esophagus, producing dysphagia. Although common on imaging in older adults, symptomatic osteophytic dysphagia is underdiagnosed, and the role of systemic anabolic factors in osteophyte growth is ...
Sui-Ling Perez +3 more
doaj +2 more sources
Advanced Biomedical Research, 2018 Background: Twine-arginine translocation (TAT) system is one of the exporting systems in Escherichia coli which could transport fully/semi-correctly folded proteins outside the reductive cytoplasmic space.
Mohammad Reza Bagherinejad +4 more
doaj +3 more sources
Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations [PDF]
Annals of Pediatric Endocrinology & MetabolismGrowth hormone (GH) is crucial for childhood growth and body composition. In pediatric GH deficiency (pGHD), the pituitary gland fails to produce sufficient GH, which affects linear growth in childhood.
Aristides K. Maniatis +4 more
doaj +2 more sources
Case Reports in PediatricsWe report an 11-year-old Hispanic male with a PPP1R12A gene de novo heterozygous likely pathogenic mutation, p. (Gln13Arg) (CAG>CGG), c.38 A > G in Exon 1 (NM_002480.2), detected on whole-exome trio sequencing during his short-stature evaluation.
Rosita Saul +4 more
doaj +2 more sources
Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
Biologics: Targets & Therapy, 2010 J Paul Frindik1, Stephen F Kemp11University of Arkansas for Medical Sciences and Arkansas Children’s Hospital, AR, USAAbstract: Idiopathic short stature (ISS) is a term that describes short stature in children who do not have growth hormone (GH)
J Paul Frindik, Stephen F Kemp
doaj +1 more source
Studies on the formulation and delivery of somatropin.
, 2004 Studies on the formulation and delivery of ...
Camellia. Zamiri (7980221)
core +6 more sources
Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study [PDF]
, 2022 Context: Somatrogon is a long-acting recombinant human growth hormone treatment developed as a once-weekly treatment for pediatric patients with growth hormone deficiency (GHD).
Carakushansky, Mauri +11 more
core +2 more sources
IGF-1 Deficiency Serves as an Integrated Biomarker Pathogenic Driver and Predictor in Poor Ovarian Response. [PDF]
Adv Sci (Weinh)IGF‐1 deficiency underlies poor ovarian response (POR), as reduced levels in follicular fluid and granulosa cells impair antral follicle formation and compromise reproductive outcomes. Including IGF‐1 as a biomarker significantly enhances the accuracy of models predicting both PORrisk and pregnancy success.
Hu Z +9 more
europepmc +2 more sources